Mass Tort brief
Tylenol Autism Lawsuits Revived as MDL Pressure Mounts
A landmark federal ruling revives over 500 acetaminophen cases, as bellwether trials begin nationwide over hernia mesh, forever chemicals, and youth social media addiction.
Mass Tort
By narrowing judges' power to screen out expert science, the court handed 500 plaintiffs their leverage back — Kenvue now faces juries, and pressure toward a settlement in the billions.
BackgroundThe mass tort system relies heavily on gatekeeping rules that empower federal judges to exclude unreliable scientific testimony before it reaches a jury. Plaintiffs' attorneys filed thousands of lawsuits claiming Tylenol exposure during pregnancy causes behavioral disorders.
- The Second Circuit ruled that U.S. District Judge Denise Cote overstepped her gatekeeping authority by throwing out the expert testimony, reviving the litigation's momentum.
- The court clarified it was not ruling on the drug's safety, but rather that the experts' methodologies met federal scientific standards, allowing the science to be presented to a jury.
- Kenvue maintains that extensive, independent global medical research shows no credible link between acetaminophen and developmental delays, signaling that the company will vigorously fight the claims before a jury.
Mass Tort
The first Symbotex hernia mesh trial sets up a high-stakes test — deciding whether Medtronic’s subsidiary faces massive multi-district litigation payouts.
BackgroundMedical device manufacturers use multi-district litigation (MDL) to consolidate thousands of similar injury lawsuits before a single federal judge. Bellwether trials serve as test cases to help both sides evaluate how juries respond to scientific evidence.
- The plaintiff alleges Covidien's Symbotex mesh was defectively designed because its protective layer degraded too quickly, causing severe organ adhesion and requiring corrective surgery.
- U.S. District Judge Patti Saris denied Covidien's motion for summary judgment, allowing design defect and failure-to-warn claims to reach the jury and forcing a high-stakes public trial.
- Covidien's parent company Medtronic has fought to dismiss the claims, but a plaintiff victory could trigger multi-million dollar settlements across thousands of related cases.
Mass Tort
Letitia James' aggressive PFAS lawsuit turns up the heat on chemical giants — seeking to hold them financially liable for the toxic footprint of everyday goods.
BackgroundPFAS (per- and polyfluoroalkyl substances) are synthetic chemicals used to resist heat, water, and grease in everyday consumer products. Because they do not break down naturally, they accumulate in human bodies and water supplies, causing serious illnesses.
- The lawsuit targets 3M, DuPont de Nemours, Chemours, and Corteva for manufacturing toxic PFAS, threatening to impose steep financial liabilities on the chemical giants.
- New York alleges the companies marketed contaminated goods for decades while keeping the public in the dark about health risks, leading to widespread drinking water contamination.
- The state is seeking hundreds of millions in damages to clean up drinking water, potentially forcing the defendant companies to finance long-term medical monitoring programs.
Mass Tort
Chemours’ last-minute settlement avoids a highly public trial — but keeps the company's $361M litigation risk front and center as more communities sue.
BackgroundChemours was spun off from DuPont in 2015 to hold its legacy chemical manufacturing liabilities, including those related to PFAS. The company's Fayetteville Works plant in North Carolina has faced continuous scrutiny for leaking toxic GenX chemicals into local drinking water.
- Grays Creek homeowners sought damages for diminished property values and emotional distress caused by contaminated wells, claiming the company ruined their groundwater.
- The settlement prevents a public jury trial that could have set a dangerous legal precedent, shielding Chemours from immediate broader courtroom exposure.
- Chemours had already accrued $361 million in PFAS-related litigation liabilities as of late last year, highlighting the escalating cost of its environmental disputes.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.